Mesoionic Oxatriazoles (MOTA): NO-Donating Characteristics and Pharmacology
Authors: Gryglewski, R.J.; Marcinkiewicz, E.; Robak, J.; Michalska, Z.; Madej, J.
Source: Current Pharmaceutical Design, Volume 8, Number 3, 1 February 2002 , pp. 167-176(10)
Publisher: Bentham Science Publishers
Abstract:
Biological role of nitric oxide (NO), functioning of isoforms of NO synthetases (NOS) and pharmacology of principle NO-donors were reviewed. NO donating characteristics and pharmacology of 23 mesoionic oxatriazoles (MOTA) were compared with those of 5-morpholinosydnonimine (SIN-1), S-nitroso-N-acetylpenicillamine (SNAP), sodium nitroprusside (NaNP) and glyceryl trinitrate (GTN). It is concluded that in vitro NO donating profile of MOTA hardly can be used as a predicting measure for their pharmacological activities either in vitro or in vivo. If anything, fast NO releasers seem to be stronger vasorelaxants than MOTA with slow NO releasing properties. Still, among representatives of this last category of MOTA one may find efficient antithrombotic and thrombolytic agents. For instance, MOTA 5-oxides were more potent thrombolytics than SIN-1, SNAP or NaNP. Also MOTA with potent anti-platelet action in vitro seem to be potent relaxants of tracheal strips. In summary, by manipulating the chemical structures of MOTA one may obtain relative selectivity towards vasorelaxant, anti-platelet, thrombolytic or tracheorelaxant properties. Thus different categories of MOTA might be designed with a hope of achieving hypotensive, antithrombotic, thrombolytic or anti-asthmatic drugs.Keywords: Mesoionic Oxatriazoles; sodium nitroprusside; Sulphonamides; sydnonimine; anti-aggregatory agents; vasorelaxant; 5-phosphodiesterase inhibitor
Document Type: Review article
DOI: http://dx.doi.org/10.2174/1381612023396311
Publication date: 2002-02-01
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- In this: publication
- By this: publisher
- In this Subject: Pharmacology
- By this author: Gryglewski, R.J. ; Marcinkiewicz, E. ; Robak, J. ; Michalska, Z. ; Madej, J.

Shopping cart
Receive new issue alert
Get Permissions